Everest Medicines Reports Impressive Growth in 2025 Interim Results with Dual-Engine Strategy Everest Medicines announced its interim results for the first half of 2025, revealing a significant 48% growth year-over-year driven by its innovative dual-engine strategy and key product advancements.

Everest Medicines Reports Impressive Growth in 2025 Interim Results with Dual-Engine Strategy #China #Shanghai #Everest_Medicines #NEFECON #VELSIPITY

Nefecon Demonstrates Kidney Benefits Independent of Baseline eGFR | Docwire News Treatment effects of nefecon were consistent independent of baseline estimated glomerular filtration rate (eGFR) among patients with IgA nephropathy (IgAN).

Treatment effects of nefecon were consistent independent of baseline eGFR among patients with IgAN. #igan #iganephropathy #nephrology #nephsky #nefecon www.docwirenews.com/post/nefecon...

Calliditas Therapeutics Unveils Promising Insights at the 62nd European Renal Association Congress Calliditas Therapeutics presented new data at the ERA Congress, showcasing findings from the Phase 3 NefIgArd study on Nefecon for IgA nephropathy

Calliditas Therapeutics Unveils Promising Insights at the 62nd European Renal Association Congress #Sweden #Stockholm #IgA_nephropathy #NEFECON #Calliditas

Targeted-Release Budesonide Shows Benefit for Patients With Severe Renal Impairment | Docwire News Nefecon, a targeted-release form of budesonide, can safely be used to treat severe renal impairment and lowers proteinuria in patients with IgA nephropathy (IgAN), a study found.

A study examined the use of #Nefecon, a targeted-release #budesonide formulation, in patients with #IgAN and severe renal impairment. #iganephropathy #nephrology #nephsky www.docwirenews.com/post/targete...

Everest Medicines Reports Remarkable Financial Growth for 2024 Fiscal Year Everest Medicines has unveiled its financial results for the 2024 fiscal year, showcasing a major revenue increase of 461% and a successful launch of NEFECON in China.

Everest Medicines Reports Remarkable Financial Growth for 2024 Fiscal Year #China #Shanghai #Everest_Medicines #NEFECON #XERAVA